share_log

Centogene Announces Initial Data From ROPAD Study Showing 90% Of Genetically Confirmed Parkinson's Patients Have LRRK2 Or GBA1 Variants; Findings Indicate 15% Of PD Cases Linked To Genetic Variants; Data Published In Brain Journal Highlights...

Benzinga ·  Aug 2 04:50

Centogene Announces Initial Data From ROPAD Study Showing 90% Of Genetically Confirmed Parkinson's Patients Have LRRK2 Or GBA1 Variants; Findings Indicate 15% Of PD Cases Linked To Genetic Variants; Data Published In Brain Journal Highlights Importance Of Genetic Testing In Gene-Targeted Trials

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment